Lifecore Biomedical reports Q3 FY2025 revenue $35.2M, net loss $14.8M, sells unused filler for $17M

LIFECORE BIOMEDICAL, INC. DE

2025-Q3 EPS reported -$1.24 revenue$92,423,000

Revenue $35.2M, down 2% YoY; CDMO revenue declined $1.5M, partially offset by HA manufacturing growth of $1.0M.
Net loss of $14.8M ($0.47 diluted loss per share) vs prior-year net income of $15.6M including $21M non-cash debt derivative gain.
Adjusted EBITDA $5.7M, down from $6.4M YoY; gross profit fell to $9.8M from $11.9M.
Sold unused high-speed isolator filler for $17M; $7M received at closing, remainder over 18 months. Signed multiple new development agreements.

item 2.02 item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001005286-25-000052
form_type: 8-K
ticker: LFCR
cik: 0001005286
company_name: LIFECORE BIOMEDICAL, INC. DE
filed_at: 2025-04-03T23:59:59+00:00
discovered_at: 2026-05-14T18:02:47.134349+00:00
generated_at: 2026-05-23T22:09:57.202815+00:00
sec_items: ["2.02", "7.01", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001005286-25-000052
json_url: https://secwatch.observer/filing/0001005286-25-000052.json
markdown_url: https://secwatch.observer/filing/0001005286-25-000052.md
text_url: https://secwatch.observer/filing/0001005286-25-000052.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000052/0001005286-25-000052-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1005286/000100528625000052/lndc-20250403.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001005286-25-000052

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.